Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience

ATALAR B., Ozsahin M., Call J., Napieralska A., Kamer S., Villa S., ...Daha Fazla

RADIOTHERAPY AND ONCOLOGY, cilt.127, sa.1, ss.96-102, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 127 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.radonc.2017.12.028
  • Dergi Adı: RADIOTHERAPY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.96-102
  • Anahtar Kelimeler: Adult medulloblastoma, Chemotherapy, Craniospinal, Multimodality, Radiotherapy, Rare Cancer Network (RCN), NONMETASTATIC MEDULLOBLASTOMA, ADJUVANT CHEMOTHERAPY, RISK MEDULLOBLASTOMA, SURVIVAL, MULTICENTER, RECURRENCE, STRATEGY
  • Gazi Üniversitesi Adresli: Evet

Özet

Background and purpose: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network.